Betta Pharmaceuticals Co. Ltd. has described hypoxia-inducible factor-2α (HIF-2α; EPAS1) inhibitors reported to be useful for the treatment of Von Hippel-Lindau disease, cancer, autoimmune disease and inflammatory disorders.
Research at Humanwell Healthcare (Group) Co. Ltd. has led to the development of heterocyclic 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitors reported to be useful for the treatment of acute lung injury, diabetes, fibrosis, graft-vs.-host disease, heart failure, inflammatory bowel disease, alopecia and osteoporosis, among others.
Research at Simcere Zaiming Pharmaceutical Co. Ltd. has led to the development of polycyclic compounds acting as E3 ubiquitin-protein ligase CBL-B inhibitors and thus reported to be useful for the treatment of cancer and autoimmune disease.
China Pharmaceutical University and Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. have jointly developed Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.
Proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to non-receptor tyrosine-protein kinase TYK2-targeting moiety have been reported in a Kymera Therapeutics Inc. patent as potentially useful for the treatment of neurological, inflammatory and endocrine disorders, autoimmune diseases, transplant rejection, graft-vs.-host disease and cancer.
Recent Perha Pharmaceuticals patents describe imidazolone derivatives acting as inhibitors of dual specificity protein kinase CLK1 and/or CLK4 and/or and dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). As such, they are reported to be useful for the treatment of diabetes, cancer, CDKL5 deficiency disorder, chromosome 22q13 deletion syndrome, Alzheimer’s disease, viral infections, Niemann-Pick disease type C and tauopathies, among others.
RSS